Replies to post #129322 on Biotech Values

[oc631]

That’s highly unlikely based on the results of the ‘C208’ study completed two years ago (#msg-43114192). VRTX is running another study to get BID dosing on the label (#msg-55917427), but BID dosing is already the de facto standard for Incivek.

By the time results of this study are released the market should be focused on all-oral if it isn't already.


Edit: That was 12-week response guided. The question remains will there be a market?